LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 249

Search options

  1. Article ; Online: Difelikefalin in Hemodialysis Patients with Pruritus. Reply.

    Fishbane, Steven

    The New England journal of medicine

    2020  Volume 382, Issue 21, Page(s) 2065–2066

    MeSH term(s) Humans ; Pruritus ; Renal Dialysis
    Language English
    Publishing date 2020-05-22
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMc2002485
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Book: Meeting the 2012 QIP (Quality incentive program) clinical measures: strategies for dialysis centers

    Fishbane, Steven / Hazzan, Azzour

    a CME supplement

    (American journal of kidney diseases ; 60,5, Suppl. 1)

    2012  

    Author's details Steven Fishbane ; Azzour Hazzan
    Series title American journal of kidney diseases ; 60,5, Suppl. 1
    Collection
    Language English
    Size S17 S.
    Publisher Saunders an imprint of Elsevier
    Publishing place New York, NY
    Publishing country United States
    Document type Book
    HBZ-ID HT017474377
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  3. Book: Management of anemia in the nephropathic patient

    Fishbane, Steven

    the hemoglobin variability phenomenon

    2008  

    Author's details Steven Fishbane
    Language English
    Size VI, 55 S. : graph. Darst.
    Publisher Wolters Kluwer Lippincott Williams & Wilkins
    Publishing place London
    Publishing country Great Britain
    Document type Book
    HBZ-ID HT016052599
    ISBN 978-0-9561387-0-5 ; 0-9561387-0-5
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  4. Book: Emerging standards of care

    Fishbane, Steven

    implications of New K/DOQU guidelines

    (American journal of kidney diseases ; 41,6, Suppl. 5)

    2003  

    Author's details guest ed.: Steven Fishbane
    Series title American journal of kidney diseases ; 41,6, Suppl. 5
    Collection
    Language English
    Size S26 S. : graph. Darst.
    Publisher Saunders
    Publishing place Philadelphia, Pa
    Publishing country United States
    Document type Book
    HBZ-ID HT013702501
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  5. Article ; Online: Improving Detection and Management of Anemia in CKD.

    Fishbane, Steven / Brunton, Stephen

    The Journal of family practice

    2022  Volume 71, Issue 6 Suppl, Page(s) S23–S28

    Abstract: Learning objectives: At the end of the activity, participants will be able to:Describe approaches to improve recognition of chronic kidney disease (CKD) and anemia in primary care. Explain the importance of early management of anemia in CKD to reduce ... ...

    Abstract Learning objectives: At the end of the activity, participants will be able to:Describe approaches to improve recognition of chronic kidney disease (CKD) and anemia in primary care. Explain the importance of early management of anemia in CKD to reduce adverse outcomes and improve symptoms. Prescribe evidence-based treatment for patients with anemia in CKD who can be managed in the primary care setting. Discuss emerging evidence for new agents being studied for treating anemia in CKD.
    MeSH term(s) Anemia/diagnosis ; Anemia/drug therapy ; Anemia/etiology ; Humans ; Renal Insufficiency, Chronic/complications ; Renal Insufficiency, Chronic/diagnosis ; Renal Insufficiency, Chronic/therapy
    Language English
    Publishing date 2022-08-12
    Publishing country United States
    Document type Journal Article
    ZDB-ID 197883-4
    ISSN 1533-7294 ; 0094-3509
    ISSN (online) 1533-7294
    ISSN 0094-3509
    DOI 10.12788/jfp.0411
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Hypoxia-inducible factor stabilizers: 27 228 patients studied, yet a role still undefined.

    Fishbane, Steven / Malieckal, Deepa A / Ng, Ji H

    Clinical kidney journal

    2023  Volume 16, Issue 5, Page(s) 776–779

    Abstract: With the emergence of hypoxia inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) came the hope that using these oral drugs could improve the treatment of the anemia of kidney disease. In this editorial we discuss the accumulated knowledge on these ...

    Abstract With the emergence of hypoxia inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) came the hope that using these oral drugs could improve the treatment of the anemia of kidney disease. In this editorial we discuss the accumulated knowledge on these agents and the clinical context for use.
    Language English
    Publishing date 2023-03-01
    Publishing country England
    Document type Editorial
    ZDB-ID 2655800-2
    ISSN 2048-8513 ; 2048-8505
    ISSN (online) 2048-8513
    ISSN 2048-8505
    DOI 10.1093/ckj/sfad026
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Difelikefalin for the treatment of moderate-to-severe pruritus associated with chronic kidney disease on hemodialysis.

    Rastogi, Anjay / Fishbane, Steven / Lerma, Edgar

    Expert review of clinical pharmacology

    2023  Volume 16, Issue 5, Page(s) 387–400

    Abstract: Introduction: Chronic kidney disease-associated pruritus (CKD-aP) is often experienced by patients with CKD receiving dialysis. Approximately 40% of hemodialysis patients are 'moderately' to 'extremely bothered' by itching, associated with reduced ... ...

    Abstract Introduction: Chronic kidney disease-associated pruritus (CKD-aP) is often experienced by patients with CKD receiving dialysis. Approximately 40% of hemodialysis patients are 'moderately' to 'extremely bothered' by itching, associated with reduced quality of life, poor sleep quality, and depression as well as worse clinical outcomes, including increased medication use, infections, hospitalizations, and mortality.
    Areas covered: This review covers the pathophysiology and treatment landscape of CKD-aP, and the development, clinical efficacy, and safety profile of difelikefalin. We summarize the existing evidence, and discuss both the position of difelikefalin in the treatment pathway and potential future developments.
    Expert opinion: Difelikefalin is a kappa opioid receptor agonist, with a primary mode of action that is outside of the central nervous system and provides an improved safety profile compared with other opioid agonists, with limited potential for abuse and dependency. Difelikefalin has demonstrated efficacy, tolerability, and safety profile in several large-scale clinical trials in more than 1,400 hemodialysis patients with CKD-aP treated for up to 64 weeks. Difelikefalin is the only approved treatment for CKD-aP in the U.S.A and Europe; other treatments are used off-label, have limited proof of efficacy in large-scale clinical trials in this patient population, and may present an increased risk of toxicity in patients with CKD.
    MeSH term(s) Humans ; Quality of Life ; Renal Insufficiency, Chronic/complications ; Renal Insufficiency, Chronic/therapy ; Renal Dialysis/adverse effects ; Pruritus/drug therapy ; Pruritus/etiology
    Chemical Substances difelikefalin (NA1U919MRO)
    Language English
    Publishing date 2023-04-13
    Publishing country England
    Document type Review ; Journal Article
    ISSN 1751-2441
    ISSN (online) 1751-2441
    DOI 10.1080/17512433.2023.2197209
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: A New View of Iron Management in Heart Failure: What Nephrologists Need to Know.

    Uppal, Nupur N / Fishbane, Steven

    Clinical journal of the American Society of Nephrology : CJASN

    2021  Volume 16, Issue 4, Page(s) 502–504

    MeSH term(s) Anemia ; Heart Failure/drug therapy ; Humans ; Iron ; Nephrologists
    Chemical Substances Iron (E1UOL152H7)
    Language English
    Publishing date 2021-03-29
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 2226665-3
    ISSN 1555-905X ; 1555-9041
    ISSN (online) 1555-905X
    ISSN 1555-9041
    DOI 10.2215/CJN.01850221
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Introduction: Iron Management in Chronic Kidney Disease.

    Fishbane, Steven

    Seminars in nephrology

    2016  Volume 36, Issue 2, Page(s) 85–86

    Language English
    Publishing date 2016-03
    Publishing country United States
    Document type Editorial
    ZDB-ID 604652-6
    ISSN 1558-4488 ; 0270-9295
    ISSN (online) 1558-4488
    ISSN 0270-9295
    DOI 10.1016/j.semnephrol.2016.02.009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Phosphate Absorption and Hyperphosphatemia Management in Kidney Disease: A Physiology-Based Review.

    Fishbane, Steven N / Nigwekar, Sagar

    Kidney medicine

    2021  Volume 3, Issue 6, Page(s) 1057–1064

    Abstract: Phosphate absorption occurs in the gastrointestinal tract through paracellular absorption and transcellular transport. The paracellular pathway does not saturate and has a significantly higher absorption capacity than does the transcellular pathway. ... ...

    Abstract Phosphate absorption occurs in the gastrointestinal tract through paracellular absorption and transcellular transport. The paracellular pathway does not saturate and has a significantly higher absorption capacity than does the transcellular pathway. Evidence indicates that this pathway is the primary mechanism of intestinal phosphate absorption, particularly with Western diets containing high amounts of phosphorus. Elevated serum phosphorus concentrations are associated with cardiovascular morbidity and mortality but serum phosphorus concentrations > 5.5 mg/dL are highly prevalent despite best efforts with dietary phosphate restriction, dialysis, and the use of phosphate binders. The efficacy of phosphate binders may be inherently limited because the mechanism of action does not target any phosphate absorption pathway. Thus, therapeutic innovations are needed to address the limitations of phosphate binders. Novel therapies leveraging new mechanistic understandings of phosphate absorption and the primacy of the paracellular pathway may improve phosphate control. Phosphate absorption inhibitors that target the pathway are a novel therapeutic class. Tenapanor is an investigational first-in-class nonbinder phosphate absorption inhibitor that inhibits the sodium-hydrogen exchanger isoform 3 to reduce paracellular permeability specific to phosphate. Phosphate absorption inhibitors may represent a new mechanistic approach to phosphate management with the potential to improve clinical outcomes.
    Language English
    Publishing date 2021-08-27
    Publishing country United States
    Document type Journal Article ; Review
    ISSN 2590-0595
    ISSN (online) 2590-0595
    DOI 10.1016/j.xkme.2021.07.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top